Bank of America’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-22,900
Closed -$920K 8430
2025
Q1
$920K Buy
+22,900
New +$1.05M ﹤0.01% 5281
2024
Q4
Sell
-70,000
Closed -$3.7M 8222
2024
Q3
$3.7M Hold
70,000
﹤0.01% 4009
2024
Q2
$3.79M Sell
70,000
-329,700
-82% -$19.9M ﹤0.01% 3880
2024
Q1
$28M Buy
399,700
+200,000
+100% +$15.5M ﹤0.01% 1962
2023
Q4
$16.7M Buy
+199,700
New +$7.23M ﹤0.01% 2350
2022
Q3
Sell
-30,000
Closed -$1.18M 7899
2022
Q2
$1.18M Buy
+30,000
New +$1.21M ﹤0.01% 4772

Other funds holding CYTK

Bank of America's CYTK Position: Q1 2026 in Review

Bank of America increased its Cytokinetics (CYTK) stake by 6.3% in Q1 2026, buying an estimated $11.7M and bringing the position to 3,125,436 shares worth $206M. The position accounts for 0.02% of the portfolio, ranked #723.

Bank of America first reported a position in CYTK in Q3 2013 and has held it in 51 quarters since. The position peaked at $335M in Q1 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Bank of America held 3,125,436 shares of Cytokinetics worth $206M as of Q1 2026.
  • Bank of America bought 184,284 Cytokinetics shares in Q1 2026, an estimated $11.7M.
  • Cytokinetics made up 0.02% of Bank of America's portfolio in Q1 2026, its #723 holding.
  • Bank of America first reported a position in Cytokinetics in Q3 2013 and has held it in 51 quarters since.
  • Bank of America's Cytokinetics position peaked at $335M in Q1 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.